Search
Feed aggregator
BridgeBio Builds on Positive Phase III Data for Acoramidis in ATTR-CM
BridgeBio Builds on Positive Phase III Data for Acoramidis in ATTR-CM 5/30/2024
Immunovant Shifts Focus to Other FcRn Inhibitor, Gives Rival Vyvgart Breathing Room
Immunovant Shifts Focus to Other FcRn Inhibitor, Gives Rival Vyvgart Breathing Room 5/30/2024
Tris Pharma Gets FDA Approval for Non-Stimulant ADHD Medication
Tris Pharma Gets FDA Approval for Non-Stimulant ADHD Medication 5/30/2024
Biohaven’s Phase I Data for Lead Protein Degrader Disappoints Investors
Biohaven’s Phase I Data for Lead Protein Degrader Disappoints Investors 5/30/2024
BioSpace x DIA: Advanced Therapy Product Regulatory Confusion
BioSpace x DIA: Advanced Therapy Product Regulatory Confusion 5/30/2024
BioNTech Secures $145M to Boost mRNA Vaccine Capabilities in Africa
BioNTech Secures $145M to Boost mRNA Vaccine Capabilities in Africa 5/30/2024
Early-Stage Biotechs Now Tying CEO Pay Packages to Capital Raises
Early-Stage Biotechs Now Tying CEO Pay Packages to Capital Raises 5/30/2024
Moving Up: 5 Tips for Transitioning From Co-Worker to Manager
Moving Up: 5 Tips for Transitioning From Co-Worker to Manager 5/30/2024
Merck’s Potential $3B EyeBio Acquisition Puts Drugmaker Back in Ophthalmology
Merck’s Potential $3B EyeBio Acquisition Puts Drugmaker Back in Ophthalmology 5/29/2024
Amgen Wins FDA Approval for First Biosimilar to AstraZeneca’s Soliris
Amgen Wins FDA Approval for First Biosimilar to AstraZeneca’s Soliris 5/29/2024
Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters
Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters 5/29/2024
Insmed Stock Surges After Brensocatib Aces Phase III Lung Disease Study
Insmed Stock Surges After Brensocatib Aces Phase III Lung Disease Study 5/29/2024
AstraZeneca’s Ambitious Target, Pharma Layoffs Continue and ASCO
AstraZeneca’s Ambitious Target, Pharma Layoffs Continue and ASCO 5/29/2024
Who Will the Next “Big Pharma” Players Be?
Who Will the Next “Big Pharma” Players Be? 5/29/2024
How Realistic is AstraZeneca’s $80B Revenue Target by 2030?
How Realistic is AstraZeneca’s $80B Revenue Target by 2030? 5/29/2024
J&J Scores Phase III Victory in Major Depressive Disorder
J&J Scores Phase III Victory in Major Depressive Disorder 5/29/2024
Biopharma IPOs From the First Half of 2024
Biopharma IPOs From the First Half of 2024 5/29/2024
Can AI Help Biopharma Companies Go Green?
Can AI Help Biopharma Companies Go Green? 5/29/2024
AstraZeneca Touts Early-Stage Results for Oral PCSK9 Inhibitor
AstraZeneca Touts Early-Stage Results for Oral PCSK9 Inhibitor 5/29/2024
J&J Inks $1.25B Deal to Buy Rights to Atopic Dermatitis Candidate from Numab
J&J Inks $1.25B Deal to Buy Rights to Atopic Dermatitis Candidate from Numab 5/28/2024
World Pharma News
- How the cheese-noodle principle could help counter Alzheimer's
- New 'sensor' lets researchers watch DNA repair in real time
- The immune system creates its own targets within viruses
- Targeted drug could benefit young patients with invasive sarcoma
- Next-generation microbiome medicine may revolutionize the treatment of Parkinson's and similar disorders